Prospect: information for the patient
Norfenazin 25 mg tablets
Nortriptilina hidrocloruro
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
1.What isNorfenazinand for what it is used
2.What you need to know beforestarting totakeNorfenazin
3.How to takeNorfenazin
4.Possible adverse effects
5Storage ofNorfenazin
6.Contents of the package and additional information
Norfenazin contains the active ingredient nortriptyline.
Nortriptyline belongs to a group of medications known as tricyclic antidepressants, used for the treatment of major depressive episode in adults.
Do not takeNorfenazin
(MAOIs - other medicines used for depression or selegiline (used to treat Parkinson's disease) or have taken them in the last 14 days: if you have taken any of these medicines, you must wait 14 days before starting to take this medicine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medicine.
Thoughts of suicide and worsening of depression
If you are depressed and/or have anxiety disorders, it is possible that you may sometimes think about harming yourself or taking your own life. These types of thoughts may increase when you first start taking antidepressants, as all these medicines take time to work, usually two weeks, but sometimes longer.
You may be more likely to have these types of thoughts:
If you have thoughts of harming yourself or taking your own life, contact your doctor or go to a hospital immediately.
It may be helpful to tell a family member or close friend that you are depressed and ask them to read this leaflet. You can ask them to tell you if they think your depression or anxiety is getting worse or if they are concerned about changes in your behavior.
Inform your doctor if you have or have had any medical problems, especially
Some patients with manic-depressive disorders may go through a manic phase. It is characterized by unusual and rapidly changing thoughts, excessive joy and excessive physical activity. In these cases, it is essential to consult your doctor.
Interval QT prolongadoprolonged QT interval
A heart problem called "prolonged QT interval" (which appears on an electrocardiogram [ECG]) and heart rhythm disorders (irregular heartbeat) have been reported with nortriptyline. Inform your doctor if:
If you are taking antidepressants such as selective serotonin reuptake inhibitors (SSRIs), your doctor may consider changing your medication dose (see also section 2 "Taking Norfenazin with other medicines" and section 3).
Children and adolescents
Do not administer this medicine to children and adolescents under 18 years old for these treatments as the safety and efficacy have not been established in this age group.
Older people
The dosage should be reduced in the elderly. Older people are more likely to experience certain side effects such as dizziness when standing up due to low blood pressure (see also section 4 "Possible side effects").
Other medicines and Norfenazin
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medicine. Some medicines may affect the functioning of other medicines and this can sometimes cause serious side effects.
You should be particularly careful if you are taking any of the following medicines: monoamine oxidase inhibitors (MAOIs) such as moclobemide (for the treatment of depression) or selegiline (used to treat Parkinson's disease). These medicines should not be taken at the same time as nortriptyline (see section 2 "Do not take Norfenazin").
You should also inform your doctor if you are taking or have taken recently medicines that may affect heart rhythm such as, for example.medicines for treating irregular heartbeats (e.g. quinidine and sotalol)
Taking Norfenazin with alcohol
Do not drink alcohol during treatment with this medicine, as it may increase its sedative effect.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Nortriptyline is not recommended during pregnancy unless your doctor considers it clearly necessary and only after careful consideration of the benefit and risk. If you have taken this medicine during the last part of pregnancy, the newborn may experience withdrawal symptoms such as irritability, increased muscle tension, tremors, irregular breathing, poor sucking, loud crying, urinary retention and constipation.
Your doctor will advise you whether to start/continue/stop breastfeeding or interrupt the use of this medicine, taking into account the benefit of breastfeeding for the baby and the benefit of treatment for you.
Driving and operating machinery
This medicine may cause drowsiness and dizziness, especially at the start of treatment. Do not drive or work with tools or machinery until you know how the treatment with nortriptyline affects you.
Norfenazin contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medicine.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially "sodium-free"
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Adults
The daily dose in adults is 25 mg, 3 or 4 times a day, starting with a low dose and adjusting the dose. It can be administered once a day, usually at night, or 3 or 4 times a day. It may take between 2 and 4 weeks to achieve a response. Doses above 150 mg per day are not recommended.
Older adults
The dosage for elderly patients is 25 to 50 mg per day in divided doses.
Treatment should be initiated with a low dose (10-20 mg per day) and increased as needed to a maximum dose of 50 mg.
If it is necessary to increase the dose in an elderly patient, the ECG should be checked and plasma nortriptyline levels monitored.
Pediatric population
Do not administer this medication to children and adolescents under 18 years old for these treatments since the safety and efficacy have not been established in this age group.
Liver and kidney insufficiency
It is recommended to reduce the dose in cases of liver or kidney insufficiency, as nortriptyline is extensively metabolized in the liver and mainly eliminated through the kidneys.
Treatment duration
Do not change the medication dose or interrupt treatment without consulting your doctor first.Continue taking this medication for as long as your doctor recommends.
The underlying disease may persist for a long time. If you stop treatment too soon, symptoms may reappear.
It is recommended to continue treatment for at least 6 months after feeling better.
If you take moreNorfenazinthan you should
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you accidentally take an extra nortriptyline tablet, you may experience or worsen side effects such as drowsiness, dry mouth, dizziness, or nausea.
The symptoms of overdose may include:
The treatment of overdose should be done with general measures, gastric lavage, and assisted respiration.
If you forgot to takeNorfenazin
Take the next dose at the usual time. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment withNorfenazin
Your doctor will decide when and how to interrupt treatment to avoid any unpleasant symptoms that may occur if treatment is stopped abruptly (e.g., headache, feeling of discomfort, insomnia, and irritability).
Therefore, nortriptyline treatment should not be stopped abruptly. The dose should be gradually reduced over a week or more.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If you notice any of the following symptoms, you should see your doctor immediately:
Rare side effects, which may affect up to 1 in 1,000 people).
Very rare side effect, which may affect up to 1 in 10,000 people).
You must undergo an eye examination immediately before you can continue treatment with this medicine. These symptoms may be a sign of acute glaucoma (Very rare side effect, which may affect up to 1 in 10,000 people).
The following side effects have been reported in the following frequencies:
Very frequent: may affect more than 1 in 10 peoplepeople
Frequent: may affect up to 1 in 10 peoplepeople
Infrequent: may affect up to 1 in 100 peoplepeople
Rare: may affect up to 1 in 1,000 peoplepeople
Very rare: may affect up to 1 in 10,000 people
Frequency not known (cannot be estimated from available data)
A higher risk of bone fractures has been observed in patients treated with this type of medication.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use: www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keepthis medicationout of the sight and reach of children.
This medication does not require special conditions for conservation.
Do not usethis medicationafter the expiration date that appears onthe packagingafter CAD.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGREpoint at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Each tablet contains 25mg of nortriptyline hydrochloride.
The other excipients are: Lactose, microcrystalline cellulose, sodium glycolate Type A (from potato), cornstarch, talc, and magnesium stearate.
Appearance of the product and content of the packaging
Norfenazain25mg tablets are white, round, and scored on one face.
The tablets are presented in a PVC/aluminum blister pack with 30 tablets
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
BIOWISE PHARMACEUTICALS, S.L.
C/Teixidors 22, Pol.Can Rubiol
07141 Marratxí - Illes Balears
Spain
Responsible for manufacturing:
TOLL MANUFACTURING SERVICES, S.L.
Aragoneses, 2
28108 Alcobendas (Madrid)
Spain
Last review date of this leaflet: July 2024
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.